A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease
- 46 Downloads
The peripheral vasospastic symptoms associated with Raynaud's disease continue to be an unsolved clinical problem. Hexopal (Hexanicotinate inositol) has shown promise in uncontrolled studies and its use in patients with Raynaud's disease may reduce such vasospasm. This study examines the effects of 4 g/day of Hexopal or placebo, during cold weather, in 23 patients with primary Raynaud's disease. The Hexopal group felt subjectively better and had demonstrably shorter and fewer attacks of vasospasm during the trial period. Serum biochemistry and rheology was not significantly different between the two groups. Although the mechanism of action remains unclear Hexopal is safe and is effective in reducing the vasospasm of primary Raynaud's disease during the winter months.
Key wordsHexopal Controlled Trial Raynaud's Disease
Unable to display preview. Download preview PDF.
- 2.Aylward, M. Hexopal in Raynaud's disease. J Intern Med Res 1979, 7, 484–491.Google Scholar
- 3.Holti, G. An experimentally-controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Intern Med Res 1979, 7, 473–483.Google Scholar
- 4.Belch, J.J.F., Drury J.K., Capell, H. et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1983, 313–315.Google Scholar
- 5.Acciari, L., Camevale, F., Della Selva, A. Thermography in the hand angiopathy from vibrating tools. Acta Therm 1976, 1, 18–28.Google Scholar
- 10.Kluft, C., Brakman, P., Veldhuyzen-Stalk, E.C., Screening of the fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in Chemical Fibrinolysis and Thrombolysis. Eds: Davidson, J.F., Samama, M.M., Desnoyers, P.C.: New York, Raven Press, 1976, Vol. 2, 57–62.Google Scholar